Hologic Inc. (HOLX) 35.62 $HOLX
Hologic Set to Possibly Pullback After Yesterday's Rally of 3.40%
Comtex SmarTrend(R) - Thu Jun 23, 12:47PM CDT
Hologic (NASDAQ:HOLX) traded in a range yesterday that spanned from a low of $34.17 to a high of $35.33. Yesterday, the shares gained 3.4%, which took the trading range above the 3-day high of $34.77 on volume of 2.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
HOLX: 35.62 (+1.51)
Hologic: FDA Okays Procleix Zika Virus Test under IND Study
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 7:51AM CDT
Hologic's (HOLX) Procleix Zika Virus Test was approved under FDA???s Investigational New Drug (IND) study protocol to detect the presence of Zika virus in donated blood.
ICUI: 108.13 (+3.15), BAX: 45.96 (+1.02), LMAT: 14.82 (+0.13), HOLX: 35.62 (+1.51)
Hologic's Zika Virus Test Gets FDA Nod for Emergency Use
Zacks Equity Research - Zacks Investment Research - Mon Jun 20, 7:58AM CDT
Hologic (HOLX) will run the Aptima Zika virus test on its market leading Panther platform, which substantially reduces hands-on time for laboratories and the potential for manual errors.
ICUI: 108.13 (+3.15), BAX: 45.96 (+1.02), LMAT: 14.82 (+0.13), HOLX: 35.62 (+1.51)
FDA Approves Use of the Procleix Zika Virus Assay from Hologic and Grifols to Screen the U.S. Blood Supply Under an IND Study Protocol
PR Newswire - Mon Jun 20, 7:00AM CDT
Hologic, Inc. (NASDAQ: HOLX) and Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS) - market-leading partners committed to blood safety - announced today that the U.S. Food and Drug Administration (FDA) has approved use of the Procleix Zika virus blood screening assay on the Procleix Panther system under the agency's Investigational New Drug (IND) study protocol.
GRFS: 16.08 (+0.26), HOLX: 35.62 (+1.51)
FDA Grants Emergency Use Authorization for Hologic's Aptima® Zika Virus Assay
PR Newswire - Fri Jun 17, 5:06PM CDT
Hologic, Inc. (Nasdaq: HOLX) announced today that the U.S. Food and Drug Administration (FDA) granted emergency use authorization for the company's new, diagnostic assay for Zika virus infection. The Aptima® Zika Virus assay is a molecular diagnostic tool for the qualitative detection of RNA from Zika virus in human serum and plasma specimens. The Aptima Zika Virus assay has not been FDA cleared or approved and is only authorized for use for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of Zika virus and/or diagnosis of Zika virus infection.
HOLX: 35.62 (+1.51)
Research and Markets - Global Microbiology Testing/Clinical Microbiology Market Value of USD 5.77 Billion by 2021 - Trends, Technologies & Forecasts Report 2016-2021 - Key Vendors: Cepheid, Hologic, Danaher Corp
PR Newswire Europe - Fri Jun 17, 11:11AM CDT
DUBLIN, June 17, 2016 /PRNewswire/ --
CPHD: 30.96 (+1.46), HOLX: 35.62 (+1.51)
Hologic: Q2 Strong on Segmental Expansion, Competition Rife
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 8:43AM CDT
Hologic (HOLX) ended second-quarter fiscal 2016 on a promising note, squarely beating the Zacks Consensus Estimate.
BSX: 22.97 (+0.31), BAX: 45.96 (+1.02), LMAT: 14.82 (+0.13), HOLX: 35.62 (+1.51)
Global Hysteroscope Market Growth of 4.5% CAGR by 2022 - Analysis, Technologies & Forecasts Report 2016-2022 - Key Vendors: Hologic, Stryker, Xion Medical - Research and Markets
BusinessWire - Fri Jun 03, 11:26AM CDT
Research and Markets has announced the addition of the "Global Hysteroscope Market Size, Share, Development, Growth and Demand Forecast to 2022" report to their offering.
HOLX: 35.62 (+1.51)
Sheryl Crow Named Hologic's National Celebrity Spokesperson for New Breast Cancer Educational Campaign
PR Newswire - Thu Jun 02, 7:00AM CDT
Hologic, Inc. (NASDAQ: HOLX) announced today that nine-time Grammy award-winning singer, songwriter and breast cancer survivor Sheryl Crow will serve as national spokesperson to educate women about a more accurate mammogram, the Genius(TM) 3D MAMMOGRAPHY(TM) exam. The Genius(TM) exam is the only mammogram proven to reduce unnecessary callbacks by up to 40 percent, and detect 41 percent more invasive cancers than conventional mammography alone.[1],[2]
HOLX: 35.62 (+1.51)
After Yesterday's Rally of 1.01% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Thu May 26, 1:06PM CDT
Hologic (NASDAQ:HOLX) traded in a range yesterday that spanned from a low of $33.46 to a high of $33.95. Yesterday, the shares gained 1.0%, which took the trading range above the 3-day high of $33.80 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
HOLX: 35.62 (+1.51)
Morning Technical Review on Medical Appliances and Equipment Stocks
ACCESSWIRE - Thu May 26, 8:16AM CDT
LONDON, UK / ACCESSWIRE / May 26, 2016 / ActiveWallSt.com announces the list of stocks featured in the Technical Morning Blog. Every morning the Active Wall St. team discusses the latest news and technical events impacting stocks and the financial markets. Companies recently featured in the blog include Boston Scientific, Abbott, Medtronic, and Hologic.
BSX: 22.97 (+0.31), ABT: 39.63 (+0.89), MDT: 85.77 (+1.51), HOLX: 35.62 (+1.51)
Global Medical Imaging Equipment Market Report 2012-2022 - Analysis, Technologies & Forecast - Key Vendors: Fonar Corp, Hologic, Siemens Healthcare - Research and Markets
BusinessWire - Tue May 17, 9:53AM CDT
Research and Markets has announced the addition of the "Global Medical Imaging Equipment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2012 to 2022" report to their offering.
HOLX: 35.62 (+1.51)
HOLOGIC INVESTIGATION ALERT - Andrews & Springer LLC Is Investigating Hologic, Inc. For Potential Breach of Fiduciary Duty
GlobeNewswire - Mon May 16, 7:03AM CDT
Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential breach of fiduciary duty claims against Hologic, Inc. ("Hologic" or the "Company"
.
HOLX: 35.62 (+1.51)
The Medicines Company Appoints Tony Kingsley as President and Chief Operating Officer
BusinessWire - Mon May 16, 6:00AM CDT
The Medicines Company (NASDAQ:MDCO) has announced the appointment of Tony Kingsley as President and Chief Operating Officer. Mr. Kingsley will help oversee the day-to-day operations of the company and will lead the company's commercial activities.
MDCO: 34.54 (+1.31), HOLX: 35.62 (+1.51)
Hologic Introduces the MyoSure® REACH Device to Help Physicians Access the Hard-to-Reach Upper Third of the Uterine Cavity
PR Newswire - Wed May 11, 7:00AM CDT
Hologic, Inc. (Nasdaq: HOLX) announced today that the MyoSure® suite of gynecologic surgical products is expanding to include the MyoSure REACH device. The MyoSure REACH device confronts the challenge of hard-to-reach uterine pathology by enabling access to the upper third of the uterine cavity1.
HOLX: 35.62 (+1.51)
New Study Further Supports Screening with Pap+HPV Together(TM) as Best Way to Detect Cervical Cancer and Pre-Cancer
PR Newswire - Tue May 03, 7:00AM CDT
A new cervical cancer screening study demonstrates that Pap+HPV Together(TM) (co-testing) remains the most effective strategy for detecting high-grade cervical lesions1,2, Hologic, Inc. (Nasdaq: HOLX) announced today. The study, published this month in Cancer Cytopathology, a peer-reviewed journal of the American Cancer Society, also showed no significant difference between the sensitivities of the Pap and HPV tests when either was used alone as a primary screening method.1
HOLX: 35.62 (+1.51)
Hologic Marks National Osteoporosis Month by Releasing New Consumer Survey
PR Newswire - Mon May 02, 7:00AM CDT
While nearly three-quarters of Americans (71%) are aware of the effects that osteoporosis can have on their health, only about half report taking any steps to prevent it,1 according to the results of a new survey announced today by Hologic (Nasdaq: HOLX). To mark the start of National Osteoporosis Month, Hologic is raising awareness of this major threat to women's health, which affects nearly 56 million Americans.
HOLX: 35.62 (+1.51)
Downgrade Alert for Hologic (HOLX)
Comtex SmarTrend(R) - Fri Apr 29, 3:45AM CDT
Hologic (NASDAQ:HOLX) was downgraded from Buy to Hold at Needham today. The stock closed yesterday at $33.92 on volume of 9.9 million shares, above average daily volume of 4.9 million. In the past 52 weeks, shares of Hologic have traded between a low of $29.71 and a high of $43.00 and closed yesterday at $33.92, which is 14% above that low price. Over the past week, the 200-day moving average (MA) has remained constant while the 50-day MA has advanced 0.8%.
HOLX: 35.62 (+1.51)
SmarTrend Watching for Potential Rebound in Shares of Hologic After 9.75% Loss
Comtex SmarTrend(R) - Thu Apr 28, 1:10PM CDT
Hologic (NASDAQ:HOLX) traded in a range yesterday that spanned from a low of $33.87 to a high of $36.25. Yesterday, the shares fell 9.8%, which took the trading range below the 3-day low of $37.33 on volume of 5.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
HOLX: 35.62 (+1.51)
Hologic Set to Possibly Pullback After Yesterday's Rally of 3.40%
Comtex SmarTrend(R) - Thu Jun 23, 12:47PM CDT
Hologic (NASDAQ:HOLX) traded in a range yesterday that spanned from a low of $34.17 to a high of $35.33. Yesterday, the shares gained 3.4%, which took the trading range above the 3-day high of $34.77 on volume of 2.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
HOLX: 35.62 (+1.51)
Hologic: FDA Okays Procleix Zika Virus Test under IND Study
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 7:51AM CDT
Hologic's (HOLX) Procleix Zika Virus Test was approved under FDA???s Investigational New Drug (IND) study protocol to detect the presence of Zika virus in donated blood.
ICUI: 108.13 (+3.15), BAX: 45.96 (+1.02), LMAT: 14.82 (+0.13), HOLX: 35.62 (+1.51)
Hologic's Zika Virus Test Gets FDA Nod for Emergency Use
Zacks Equity Research - Zacks Investment Research - Mon Jun 20, 7:58AM CDT
Hologic (HOLX) will run the Aptima Zika virus test on its market leading Panther platform, which substantially reduces hands-on time for laboratories and the potential for manual errors.
ICUI: 108.13 (+3.15), BAX: 45.96 (+1.02), LMAT: 14.82 (+0.13), HOLX: 35.62 (+1.51)
FDA Approves Use of the Procleix Zika Virus Assay from Hologic and Grifols to Screen the U.S. Blood Supply Under an IND Study Protocol
PR Newswire - Mon Jun 20, 7:00AM CDT
Hologic, Inc. (NASDAQ: HOLX) and Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS) - market-leading partners committed to blood safety - announced today that the U.S. Food and Drug Administration (FDA) has approved use of the Procleix Zika virus blood screening assay on the Procleix Panther system under the agency's Investigational New Drug (IND) study protocol.
GRFS: 16.08 (+0.26), HOLX: 35.62 (+1.51)
FDA Grants Emergency Use Authorization for Hologic's Aptima® Zika Virus Assay
PR Newswire - Fri Jun 17, 5:06PM CDT
Hologic, Inc. (Nasdaq: HOLX) announced today that the U.S. Food and Drug Administration (FDA) granted emergency use authorization for the company's new, diagnostic assay for Zika virus infection. The Aptima® Zika Virus assay is a molecular diagnostic tool for the qualitative detection of RNA from Zika virus in human serum and plasma specimens. The Aptima Zika Virus assay has not been FDA cleared or approved and is only authorized for use for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of Zika virus and/or diagnosis of Zika virus infection.
HOLX: 35.62 (+1.51)
Research and Markets - Global Microbiology Testing/Clinical Microbiology Market Value of USD 5.77 Billion by 2021 - Trends, Technologies & Forecasts Report 2016-2021 - Key Vendors: Cepheid, Hologic, Danaher Corp
PR Newswire Europe - Fri Jun 17, 11:11AM CDT
DUBLIN, June 17, 2016 /PRNewswire/ --
CPHD: 30.96 (+1.46), HOLX: 35.62 (+1.51)
Hologic: Q2 Strong on Segmental Expansion, Competition Rife
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 8:43AM CDT
Hologic (HOLX) ended second-quarter fiscal 2016 on a promising note, squarely beating the Zacks Consensus Estimate.
BSX: 22.97 (+0.31), BAX: 45.96 (+1.02), LMAT: 14.82 (+0.13), HOLX: 35.62 (+1.51)
Global Hysteroscope Market Growth of 4.5% CAGR by 2022 - Analysis, Technologies & Forecasts Report 2016-2022 - Key Vendors: Hologic, Stryker, Xion Medical - Research and Markets
BusinessWire - Fri Jun 03, 11:26AM CDT
Research and Markets has announced the addition of the "Global Hysteroscope Market Size, Share, Development, Growth and Demand Forecast to 2022" report to their offering.
HOLX: 35.62 (+1.51)
Sheryl Crow Named Hologic's National Celebrity Spokesperson for New Breast Cancer Educational Campaign
PR Newswire - Thu Jun 02, 7:00AM CDT
Hologic, Inc. (NASDAQ: HOLX) announced today that nine-time Grammy award-winning singer, songwriter and breast cancer survivor Sheryl Crow will serve as national spokesperson to educate women about a more accurate mammogram, the Genius(TM) 3D MAMMOGRAPHY(TM) exam. The Genius(TM) exam is the only mammogram proven to reduce unnecessary callbacks by up to 40 percent, and detect 41 percent more invasive cancers than conventional mammography alone.[1],[2]
HOLX: 35.62 (+1.51)
After Yesterday's Rally of 1.01% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Thu May 26, 1:06PM CDT
Hologic (NASDAQ:HOLX) traded in a range yesterday that spanned from a low of $33.46 to a high of $33.95. Yesterday, the shares gained 1.0%, which took the trading range above the 3-day high of $33.80 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
HOLX: 35.62 (+1.51)
Morning Technical Review on Medical Appliances and Equipment Stocks
ACCESSWIRE - Thu May 26, 8:16AM CDT
LONDON, UK / ACCESSWIRE / May 26, 2016 / ActiveWallSt.com announces the list of stocks featured in the Technical Morning Blog. Every morning the Active Wall St. team discusses the latest news and technical events impacting stocks and the financial markets. Companies recently featured in the blog include Boston Scientific, Abbott, Medtronic, and Hologic.
BSX: 22.97 (+0.31), ABT: 39.63 (+0.89), MDT: 85.77 (+1.51), HOLX: 35.62 (+1.51)
Global Medical Imaging Equipment Market Report 2012-2022 - Analysis, Technologies & Forecast - Key Vendors: Fonar Corp, Hologic, Siemens Healthcare - Research and Markets
BusinessWire - Tue May 17, 9:53AM CDT
Research and Markets has announced the addition of the "Global Medical Imaging Equipment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2012 to 2022" report to their offering.
HOLX: 35.62 (+1.51)
HOLOGIC INVESTIGATION ALERT - Andrews & Springer LLC Is Investigating Hologic, Inc. For Potential Breach of Fiduciary Duty
GlobeNewswire - Mon May 16, 7:03AM CDT
Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential breach of fiduciary duty claims against Hologic, Inc. ("Hologic" or the "Company"
. HOLX: 35.62 (+1.51)
The Medicines Company Appoints Tony Kingsley as President and Chief Operating Officer
BusinessWire - Mon May 16, 6:00AM CDT
The Medicines Company (NASDAQ:MDCO) has announced the appointment of Tony Kingsley as President and Chief Operating Officer. Mr. Kingsley will help oversee the day-to-day operations of the company and will lead the company's commercial activities.
MDCO: 34.54 (+1.31), HOLX: 35.62 (+1.51)
Hologic Introduces the MyoSure® REACH Device to Help Physicians Access the Hard-to-Reach Upper Third of the Uterine Cavity
PR Newswire - Wed May 11, 7:00AM CDT
Hologic, Inc. (Nasdaq: HOLX) announced today that the MyoSure® suite of gynecologic surgical products is expanding to include the MyoSure REACH device. The MyoSure REACH device confronts the challenge of hard-to-reach uterine pathology by enabling access to the upper third of the uterine cavity1.
HOLX: 35.62 (+1.51)
New Study Further Supports Screening with Pap+HPV Together(TM) as Best Way to Detect Cervical Cancer and Pre-Cancer
PR Newswire - Tue May 03, 7:00AM CDT
A new cervical cancer screening study demonstrates that Pap+HPV Together(TM) (co-testing) remains the most effective strategy for detecting high-grade cervical lesions1,2, Hologic, Inc. (Nasdaq: HOLX) announced today. The study, published this month in Cancer Cytopathology, a peer-reviewed journal of the American Cancer Society, also showed no significant difference between the sensitivities of the Pap and HPV tests when either was used alone as a primary screening method.1
HOLX: 35.62 (+1.51)
Hologic Marks National Osteoporosis Month by Releasing New Consumer Survey
PR Newswire - Mon May 02, 7:00AM CDT
While nearly three-quarters of Americans (71%) are aware of the effects that osteoporosis can have on their health, only about half report taking any steps to prevent it,1 according to the results of a new survey announced today by Hologic (Nasdaq: HOLX). To mark the start of National Osteoporosis Month, Hologic is raising awareness of this major threat to women's health, which affects nearly 56 million Americans.
HOLX: 35.62 (+1.51)
Downgrade Alert for Hologic (HOLX)
Comtex SmarTrend(R) - Fri Apr 29, 3:45AM CDT
Hologic (NASDAQ:HOLX) was downgraded from Buy to Hold at Needham today. The stock closed yesterday at $33.92 on volume of 9.9 million shares, above average daily volume of 4.9 million. In the past 52 weeks, shares of Hologic have traded between a low of $29.71 and a high of $43.00 and closed yesterday at $33.92, which is 14% above that low price. Over the past week, the 200-day moving average (MA) has remained constant while the 50-day MA has advanced 0.8%.
HOLX: 35.62 (+1.51)
SmarTrend Watching for Potential Rebound in Shares of Hologic After 9.75% Loss
Comtex SmarTrend(R) - Thu Apr 28, 1:10PM CDT
Hologic (NASDAQ:HOLX) traded in a range yesterday that spanned from a low of $33.87 to a high of $36.25. Yesterday, the shares fell 9.8%, which took the trading range below the 3-day low of $37.33 on volume of 5.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
HOLX: 35.62 (+1.51)
